In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche and Amgen Watched in Challenge over EPO

Executive Summary

Published in May's RPM Report as "A CERA-ous Challenge to Amgen's EPO Franchise?" How serious is the follow-on biological challenge from Roche's CERA to Amgen Inc.'s $6 billion erythropoietin (Epogen) franchise? Serious enough to move Amgen from a growth favorite to a biotech bargain. Serious enough to threaten the ability of Amgen and Procrit manufacturer Johnson & Johnson Inc. to find new dollars in the EPO world market in 2009 and beyond.

You may also be interested in...



Why EPO Matters

Dramatic events in the EPO market--roiled by patent fights, biosimilars, and next-generation products--are important not merely to the current EPO players. They affect nearly all large-molecule companies.

Why EPO Matters

Dramatic events in the EPO market--roiled by patent fights, biosimilars, and next-generation products--are important not merely to the current EPO players. They affect nearly all large-molecule companies.

FibroGen Wins Big Upfront, Keeps US Rights to Oral Anemia Drug

Astellas Pharma badly wanted to expand its rights to FibroGen's oral anemia compounds beyond Japan. So badly, in fact, that it paid a whopping $300 million up front, agreed to up to $465 million in pre-approval milestones, and will fund half of the compounds' development in Europe and North America. Yet Astellas doesn't even get North American commercial rights in exchange: it had to settle for European and other ex-US territories.

Related Companies

UsernamePublicRestriction

Register

MT125590

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel